Developmental changes in soluble CD40 ligand

被引:18
作者
Cholette, Jill M. [1 ]
Blumberg, Neil [2 ]
Phipps, Richard P. [3 ]
Mcdermott, Michael P. [4 ]
Gettings, Kelly F. [2 ]
Lerner, Norma B. [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY USA
[2] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY USA
[3] Univ Rochester, Med Ctr, Dept Environm Sci, Rochester, NY USA
[4] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY USA
关键词
D O I
10.1016/j.jpeds.2007.06.036
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives To determine if soluble CD40 ligand (sCD40L;.formally CD154) levels van, with age and to identify age-dependent ranges in healthy pediatric and adult populations. Study design sCD40L was measured in 25 neonates. 74 children (3 months-15 years of age) and 20 adults using air enzyme-linked immunosorbent assay. For age group comparisons, Mann-Whitney tests were performed. Correlation coefficients assessed relationships between plasma and serum sCD40L. Results Plasma sCD40L levels were higher in neonates than in all other age groups, (P <.001). All grouped pediatric plasma levels were significantly higher than in adults (P <.0001). There were no significant differences in plasma sCD40L between pediatric age groups. Serum levels were significantly higher in neonates than in any other age group (P <.0001). Pediatric and adult serum sCD40L levels were not significantly different. Conclusions Plasma sCD40L levels are highest at birth and remain higher than those in adults throughout childhood. Reasons for such developmental changes remain to be investigated. Age-appropriate reference ranges should be used when sCD40L is being evaluated in pediatric disorders.
引用
收藏
页码:50 / 54
页数:5
相关论文
共 30 条
[1]   Platelet-derived CD40L -: The switch-hitting player of cardiovascular disease [J].
André, P ;
Nannizzi-Alaimo, L ;
Prasad, SK ;
Phillips, DR .
CIRCULATION, 2002, 106 (08) :896-899
[2]   CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism [J].
André, P ;
Prasad, KSS ;
Denis, CV ;
He, M ;
Papalia, JM ;
Hynes, RO ;
Phillips, DR ;
Wagner, DD .
NATURE MEDICINE, 2002, 8 (03) :247-252
[3]   Soluble CD40 ligand and platelets: Self-perpetuating pathogenic loop in thrombosis and inflammation? [J].
Aukrust, P ;
Damas, JK ;
Solum, NO .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2326-2328
[4]   Should soluble CD40 ligand be measured from serum or plasma samples? [J].
Bereczki, D ;
Nagy, E ;
Pál, A ;
Magyar, MT ;
Balla, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (06) :1129-1130
[5]  
Blake GJ, 2003, ARTERIOSCL THROM VAS, V23, P1130
[6]   Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty [J].
Cipollone, F ;
Ferri, C ;
Desideri, G ;
Paloscia, L ;
Materazzo, G ;
Mascellanti, M ;
Fazia, M ;
Iezzi, A ;
Cuccurullo, C ;
Pini, B ;
Bucci, M ;
Santucci, A ;
Cuccurullo, F ;
Mezzetti, A .
CIRCULATION, 2003, 108 (22) :2776-2782
[7]  
Conde ID, 2003, NEW ENGL J MED, V348, P2575
[8]   Soluble CD40 ligand in pulmonary arterial hypertension -: Possible pathogenic role of the interaction between platelets and endothelial cells [J].
Damås, JK ;
Otterdal, K ;
Yndestad, A ;
Aass, H ;
Solum, NO ;
Froland, SS ;
Simonsen, S ;
Aukrust, P ;
Andreassen, AK .
CIRCULATION, 2004, 110 (08) :999-1005
[9]   Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets [J].
Garlichs, CD ;
Eskafi, S ;
Raaz, D ;
Schmidt, A ;
Ludwig, J ;
Herrmann, M ;
Klinghammer, L ;
Daniel, WG ;
Schmeisser, A .
HEART, 2001, 86 (06) :649-655
[10]   Soluble CD40 ligand in acute coronary syndromes [J].
Heeschen, C ;
Dimmeler, S ;
Hamm, CW ;
van den Brand, MJ ;
Boersma, E ;
Zeiher, AM ;
Simoons, ML ;
CAPTURE Study Investigators .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (12) :1104-1111